Trastuzumab treatment in multiple lines: Current data and future directions

Clinical Breast Cancer

Volumn 12, Issue 1, 2012, Pages 10-18

  Pegram, M ^a   Liao, J ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Breast cancer; Disease progression; HER2; Metastases; Trastuzumab

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; GEMCITABINE; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG SAFETY; HEART DISEASE; HUMAN; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84856035716     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.07.003     Document Type: Review

References (53)

1. E.H. Romond, E.A. Perez, J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
2. D.J. Slamon, W. Eiermann, N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
3. E.A. Perez, E.H. Romond, V.J. Suman Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J Clin Oncol 29 2011 3366 3373
4. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
5. I. Smith, M. Procter, R.D. Gelber 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36 (Pubitemid 46039831)
6. A.U. Buzdar, V. Valero, N.K. Ibrahim Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clin Cancer Res 13 2007 228 233 (Pubitemid 46121873)
7. L. Gianni, W. Eiermann, V. Semiglazov Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised, controlled superiority trial with a parallel HER2-negative cohort Lancet 375 2010 377 384
8. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
9. M.A. Cobleigh, C.L. Vogel, D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648 (Pubitemid 29415219)
10. Y. Wong, R. Ottesen, J. Niland Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCC) J Clin Oncol 26 suppl 15 2008 342s (abstract 6522)
11. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer V.2.2011. National Comprehensive Cancer Network [website] http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf Accessed: February 9, 2011
12. R.J. Pietras, M.D. Pegram, R.S. Finn Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Oncogene 17 1998 2235 2249 (Pubitemid 28515376)
13. K. Fujimoto-Ouchi, F. Sekiguchi, M. Kazushige Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy Proc Am Assoc Cancer Res 46 2005 (abstract 5062)
14. D. Tripathy, D.J. Slamon, M. Cobleigh Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 22 2004 1063 1070 (Pubitemid 41095039)
15. L. Pusztai, F.J. Esteva Continued use of trastuzumab (Herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer Cancer Invest 24 2006 187 191
16. K.A. Gelmon, J. Mackey, S. Verma Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories Clin Breast Cancer 5 2004 52 58 (Pubitemid 38821191)
17. H.J. Stemmler, S. Kahlert, W. Siekiera Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) Onkologie 28 2005 582 586 (Pubitemid 41513144)
18. P. Tokajuk, B. Czartoryska-Arlukowicz, M.Z. Wojtukiewicz Activity of trastuzumab-based therapy beyond disease progression in heavily pretreated metastatic breast cancer patients single institution experience J Clin Oncol 24 suppl 18 2006 614s (abstract 13159)
19. T. Waddell, A. Kotsori, A. Constantinidou Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience Cancer Res 70 suppl 24 2010 449s 450s
20. G. Fountzilas, E. Razis, D. Tsavdaridis Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group Clin Breast Cancer 4 2003 120 125 (Pubitemid 36939418)
21. J. Garca-Senz, M. Martn, C. Bueno Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer J Clin Oncol 24 suppl 18 2006 577s (abstract 10617)
22. A. Fabi, G. Metro, G. Ferretti Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies Breast 17 2008 499 505
23. G. Cancello, E. Montagna, D. D'Agostino Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer Breast Cancer Res 10 2008 R60
24. F. Montemurro, G. Viale, M. Donadio Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era Clin Breast Cancer 8 2008 436 442
25. F. Montemurro, S. Redana, F. Nol Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study BMC Cancer 8 2008 209
26. G. Metro, A. Fabi, D. Giannarelli Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer J Clin Oncol 26 suppl 15s 2008 58s (abstract 1071)
27. C. Christodoulou, G. Klouvas, A. Pateli Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer Anticancer Res 23 2003 737 744 (Pubitemid 36358482)
28. R. Bartsch, C. Wenzel, D. Hussian Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least 1 earlier combination: an observational study BMC Cancer 6 2006 63
29. L. Orlando, A. Cardillo, R. Ghisini Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer BMC Cancer 6 2006 225
30. N. Bangemann, A. Kuhle, R.G. Willrodt Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab (HERceptin) and chemotherapy Breast Cancer Res Treat 64 2000 123 (530a)
31. ®) plus vinorelbine beyond disease progression in women with HER2-positive metastatic breast cancer Proc Breast Cancer Symp 179 2007 abstract 243
32. R. Bartsch, C. Wenzel, S.P. Gampenrieder Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer Cancer Chemother Pharmacol 62 2008 903 910
33. A. Morabito, R. Longo, D. Gattuso Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer Oncol Rep 16 2006 393 398
34. R. Bartsch, C. Wenzel, G. Altorjai Combination of capecitabine and trastuzumab is effective in heavily pretreated patients with metastatic breast cancer Proc Breast Symp 136 2007 (abstract 154)
35. F. Andr, M. Campone, S.A. Hurvitz Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab J Clin Oncol 26 suppl 15 2008 41s (abstract 1003)
36. F. Montemurro, R. Faggiuolo, S. Redana Continuation of trastuzumab beyond disease progression J Clin Oncol 23 2005 2866 2868 discussion 2868-9 (Pubitemid 46179483)
37. J. Baselga, K.A. Gelmon, S. Verma Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 2010 1138 1144
38. ®) may provide a survival benefit for women with HER2-positive metastatic breast cancer: data from the Hermine Cohort study Proc Breast Symp 2007 173 (abstract 230)
39. J.M. Extra, E.C. Antoine, A. Vincent-Salomon Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: The Observational Hermine Study Oncologist 15 2010 799 809
40. H.S. Rugo, P.A. Kaufman, M. Ulcickas Wood registHER: an observational cohort study of survival of patients with HER2-positive metastatic breast cancer and use of trastuzumab following progression Cancer Res 69 suppl 2 2009 250s (abstract 3142)
41. G. von Minckwitz, A. du Bois, M. Schmidt Trastuzumab beyond progression in human epidermal growth factor receptor 2positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study J Clin Oncol 27 2009 1999 2006
42. G. von Minckwitz, K. Schwedler, M. Schmidt Final overall survival analysis of the TBP phase III study (GBG 26 / BIG 3-05): capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment Cancer Res 70 suppl 24 2010 459s (abstract P6-14-05)
43. C.E. Geyer, J. Forster, D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743 (Pubitemid 46021510)
44. K.L. Blackwell, H.J. Burstein, A.M. Storniolo Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 2010 1124 1130
45. K.L. Blackwell, H.J. Burstein, G. Sledge Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy Cancer Res 69 24 suppl 2009 499s (abstract 61)
46. I. Lang, R. Bell, F. Feng Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer J Clin Oncol 29 15s 2011 63s (abstr 575)
47. M. Munoz-Mateu, A. Urruticoechea, R. Separovic Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: a multicenter, randomized, two-arm, phase II study (PHEREXA) J Clin Oncol 29 suppl 15 2011 11s (abstr TPS118)
48. M. Pegram, S. Hsu, G. Lewis Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 1999 2241 2251 (Pubitemid 29186925)
49. M.D. Pegram, A. Lopez, G. Konecny Trastuzumab and chemotherapeutics: drug interactions and synergies Semin Oncol 27 Suppl 11 2000 21 25 (Pubitemid 32172252)
50. A. Mannocci, E. De Feo, C. de Waure Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies Tumori 96 2010 385 391
51. R. Bartsch, C. De Vries, U. Pluschnig Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer BMC Cancer 9 2009 367
52. C. Portera, J. Walshe, D. Rosing Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer Clin Cancer Res 14 2008 2710 2716
53. J. Baselga, K. Imadalou, V. Paton Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab Cancer Res 69 suppl 2 2009 249s (abstract 3138)